CTOs on the Move

Integrated Recovery Products

www.irpusa.com

 
Integrated Recovery Products is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.irpusa.com
  • 1945 Placentia Ave Ste c1
    Costa Mesa, CA USA 92627
  • Phone: 949.548.8314

Executives

Name Title Contact Details

Similar Companies

General Systems Designs Inc

General Systems Designs Inc is a Cedar Rapids, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hero

Hero was founded to be the world`s most people-focused healthcare company by creating frictionless solutions to the most challenging problems facing patients and caregivers.

Stonegate Community Health Centre

Stonegate Community Health Centre is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Doheny Eye Institute

Doheny Eye Institute is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Doheny Eye Institute is based in Los Angeles, CA. You can find more information on Doheny Eye Institute at www.doheny.org

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.